Bain Capital Public Equity Management’s Larimar Therapeutics LRMR Stock Holding History

Bain Capital Public Equity Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-55,540	Closed	-$23.1M	–	42
2015 Q2	$23.1M	Hold	55,540	–	–	0.6%	34
2015 Q1	$26.4M	Hold	55,540	–	–	0.66%	36
2014 Q4	$20.6M	Hold	55,540	–	–	0.51%	47
2014 Q3	$13.1M	Hold	55,540	–	–	0.34%	51
2014 Q2	$13.2M	Buy	+55,540	New	+$13.2M	0.32%	51

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bain Capital Public Equity Management's LRMR Position: Q3 2015 in Review

Bain Capital Public Equity Management sold out of Larimar Therapeutics (LRMR) in Q3 2015, closing a stake of 55,540 shares — an estimated $23.1M sold.

Bain Capital Public Equity Management first reported a position in LRMR in Q2 2014 and held it in 5 quarters. The position peaked at $26.4M in Q1 2015. 96 funds tracked by Wall St. Rank hold LRMR as of Q3 2015.

Bain Capital Public Equity Management reported no remaining Larimar Therapeutics position as of Q3 2015 after selling out during the quarter.
Bain Capital Public Equity Management sold 55,540 Larimar Therapeutics shares in Q3 2015, an estimated $23.1M.
Bain Capital Public Equity Management first reported a position in Larimar Therapeutics in Q2 2014 and held it in 5 quarters.
Bain Capital Public Equity Management's Larimar Therapeutics position peaked at $26.4M in Q1 2015.
96 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2015.

Based on Bain Capital Public Equity Management's 13F filing for Q3 2015, filed 13 Nov 2015.